Alfred A. Rabow

AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and <i>ESR1</i> -Mutant Breast Tumors in Preclinical Models

Hazel M. Weir, Robert H. Bradbury, Mandy Lawson et al. · Cancer Research · 2016 · 174 citations

Medicine, Oncology, Pharmacology +16

Optimization of a Novel Binding Motif to (<i>E</i>)-3-(3,5-Difluoro-4-((1<i>R</i>,3<i>R</i>)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1<i>H</i>-pyrido[3,4-<i>b</i>]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist

Chris De Savi, Robert H. Bradbury, Alfred A. Rabow et al. · Journal of Medicinal Chemistry · 2015 · 160 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies

Garrett W. Rhyasen, Maureen M. Hattersley, Yi Yao et al. · Molecular Cancer Therapeutics · 2016 · 157 citations · Full text

Medicine, Oncology, Pharmacology +17

Mining the National Cancer Institute's Tumor-Screening Database:  Identification of Compounds with Similar Cellular Activities

Alfred A. Rabow, Robert H. Shoemaker, Edward A. Sausville et al. · Journal of Medicinal Chemistry · 2002 · 135 citations

Medicine, Bioinformatics, Oncology +15

Potent and selective bivalent inhibitors of BET bromodomains

Michael J. Waring, Huawei Chen, Alfred A. Rabow et al. · Nature Chemical Biology · 2016 · 135 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +12